Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
NLS Pharmaceutics
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The subject must complete all Study NLS-1021 study requirements and assessments up to Visit 6;
The subject is able, in the opinion of the Investigator, to receive NLS-2 for the 24-week Treatment Phase of this study;
Biological females of childbearing potential must agree to use a medically acceptable double-barrier method of contraception for at least 30 days prior to Day 1 and until completion of the study;
The subject is able to comply with the open-labelled extension design schedule and other study requirements;
The subject provides written informed consent for the open-label extension study.
You may not be if
The subject receives any investigational drug (other than the COVID-19 vaccine) that is not NLS-2.
Clareo Health | An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy
